Human lung deposition data: The bridge between in vitro and clinical evaluations for inhaled drug products?

International Journal of Pharmaceutics

Volumn 208, Issue 1-2, 2000, Pages 49-60

  Newman, Stephen P ^a   Wilding, Ian R ^a   Hirst, Peter H ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

Clinical response; Inhaled drugs; Lung deposition; Particle size

Indexed keywords

DRUG;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS;

EID: 0034605693     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00538-X     Document Type: Article

References (56)

1. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes
2. Pulmonary delivery of therapeutic peptides and proteins
3. An analysis of the Fraunhofer diffraction method for particle size distribution analysis and its application to aerosolized sprays
4. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler
5. Efficacy and safety of inhaled corticosteroids: New developments
6. Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects
7. Asta Medica multidose dry powder inhaler
8. In vivo characterization of inhaled pharmaceuticals using quantitative positron emission tomography
9. The inhalation device influences lung deposition and bronchodilating effect of terbutaline
10. CFC-BDP requires 2.6 times the dose to achieve equivalent improvement in FEV1 as HFA-BDP
11. Drug delivery via the respiratory tract
12. Towards meaningful laboratory tests for evaluation of pharmaceutical aerosols
13. Medical aerosol inhalers: Past, present and future
14. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers
15. Relationship between airway deposition and effects for inhaled bronchodilators
16. Optimal inhalation procedure for the fenoterol powder inhaler
17. Methods of aerosol particle size characterisation
18. Determination of the relative bioavailability of salbutamol to the lung following inhalation
19. Cumulative dose-response study of non-CFC propellant HFA-134a salbutamol sulphate metered dose inhaler in patients with asthma
20. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels inpatients with diabetes
21. The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma
22. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone
23. Dose-ranging study comparing a new soft mist inhaler with a conventional metered dose inhaler (MDI) to deliver fenoterol in patients with asthma
24. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airways obstruction
25. Characteristics of radiolabelled versus unlabelled formulations
26. New aerosol delivery systems
27. Scintigraphic assessment of pulmonary delivery systems
28. How well do in vitro particle size measurements predict drug delivery in vivo?
29. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs?
30. Understanding regional lung deposition in gamma scintigraphy
31. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medications
32. Imaging techniques for assessing drug delivery in man
33. Scintigraphic comparison of budesonide deposition from two dry powder inhalers
34. Pulmonary delivery of ergotamine tartrate using a new breath-actuated pressurized aerosol device, the aerosol drug delivery system
35. Comparison of the extrapulmonary beta-2 adrenoceptor responses and pharmacokinetics of salbutamol metered dose-inhaler and modified actuator device
36. Aerodynamic particle size testing using a time-of-flight aerosol beam spectrotrometer
37. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition
38. Airway deposition and airway effects of antiasthma drugs delivered from metered dose inhalers
39. How to use a Rotahaler
40. A new method of quantification of the pulmonary regional distribution of aerosols using combined CT and SPECT and its application to nedocromil sodium administered by metered dose inhaler
41. Determining equivalence of inhaled medications
42. Delivery devices for inhaled asthma medication
43. Assessing lung deposition of inhaled medications
44. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler p-MDI
45. Drug delivery to the respiratory tract using dry powder inhalers
46. General tests and assays
47. Delivery of fenoterol via Respimat, a novel soft mist inhaler: A randomised double-blind placebo-controlled cross-over dose-ranging study in asthmatic patients
48. Budesonide Clickhaler formulation development: Does in vitro aerosol performance predict in vivo lung delivery?
49. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence
50. Boehringer Ingelheim nebulizer BINEB. A new approach to inhalation therapy
51. Optimizing the in vitro performance of Respimat